Did Monopar Therapeutics MNPR insiders buy or sell in the past 90 days?

Q: Did Monopar Therapeutics MNPR insiders buy or sell in the past 90 days?

In the past 90 days insiders filed 0 purchases and 4 sales on the open market. Sales came to $2.6M.

Stocks

Monopar Therapeutics MNPR

Health care sectorNasdaq

What to see in Monopar Therapeutics now

Is stock about to come to market?$3.9M

$3.9M of planned sales filed in 30 days · 0.7% of the units outstanding

Filed 10/01

Is Wall Street adding or cutting?+14

96 13F filers hold it · +14 against the quarter before · shares held −0.2%

Holdings of 06/30

Who bought more than 5%?4.7%

Saturn V Capital Management holds 4.7% · −0.5pp on the report before

Filed 08/12

Company

Exchange: Nasdaq
Sector: Health care
Industry: Pharmaceutical Preparations
Headquarters: Wilmette, Illinois
Fiscal year end: 12/31
Next earnings: 11/11, estimated

96 13F filers hold it · +14 against the quarter before · shares held −0.2%Holdings of 06/30
Saturn V Capital Management holds 4.7% · −0.5pp on the report beforeFiled 08/12

Funds

13F filers: 96 · +14 since the quarter before · 06/30 holdings

Famous funds that held Monopar Therapeutics in their latest 13F report.

Fund	Shares	Value	Share of the portfolio	Since the quarter before
Mirae Asset Global ETFS HoldingsMonopar Therapeutics MNPR · 06/30 holdings	2,076 sh	$192.2K	<0.1%	No quarter before

All tracked funds

5% stakes

	Holder			Kind
08/12	Saturn V Capital Management08/12	4.7%313,384 sh	−0.5pp	13G passiveAmendment
08/12	Adage Capital Management08/12	4.76%324,195 sh	−1.5pp	13G passiveAmendment
05/15	Saturn V Capital Management05/15	5.2%345,626 sh	First report	13G passive
05/13	Adage Capital Management05/13	6.23%424,195 sh	−3.6pp	13G passiveAmendment
01/30	Tactic Pharma01/30	4.5%307,370 sh	−3.0pp	13DAmendment
25/09/24	Tactic Pharma25/09/24	7.5%506,199 sh	No earlier report	13DAmendment
25/05/14	Janus Henderson Group25/05/14	18.6%1,134,406 sh	+1.4pp	13G passiveAmendment
25/02/12	Adage Capital Management25/02/12	9.86%599,195 sh	First report	13G passive

All 5% stake reports on Monopar Therapeutics

26-week trading

No member of Congress reported a trade in Monopar Therapeutics MNPR in the past 90 days. Insiders filed 0 purchases and 4 sales on the open market over the same period, a net sale of $2.6M.

Common questions

Did Monopar Therapeutics MNPR insiders buy or sell in the past 90 days?: In the past 90 days insiders filed 0 purchases and 4 sales on the open market. Sales came to $2.6M.